Biotech Values

[mcbio]

It’s not written in stone, but it’s very likely that two successes among the three Eyeguard studies will be necessary for FDA approval. This is XOMA’s own take on the situation.

Thanks Dew. In this case, I would have preferred that the lowest-hanging fruit not be the last to report.